Login to Your Account



Dendreon Shares Surge, As Do Others In Cancer Immunotherapy

By Aaron Lorenzo


Monday, April 2, 2007
If therapeutic cancer vaccine developers were in need of a shot in the arm, they got it last week. Several firms working in the space saw their stock values make measurable gains on Friday, riding the coattails of Dendreon Corp., which Thursday received a positive endorsement from an FDA advisory committee reviewing Provenge (sipuleucel T). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription